Dose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis.
anorexia
appetite
cachexia
cancer
megestrol acetate
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
20 Jun 2024
20 Jun 2024
Historique:
revised:
10
03
2024
received:
03
01
2023
accepted:
23
04
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
20
7
2024
Statut:
aheadofprint
Résumé
There is inconsistent evidence relating to the effects of megestrol acetate (MA) supplementation on cancer patients suffering from anorexia-cachexia syndrome. This review aimed to examine the dose-response effect of MA supplementation in patients with cancer-associated anorexia/cachexia. Relevant keywords were searched in PubMed, Scopus and ISI Web of Science from inception to June 2023 for randomized controlled trials (RCTs) examining the effect of MA on pathologies in patients with cancer-associated cachexia. Our primary outcomes were changes in body weight and appetite. However, fatigue and quality of life were secondary outcomes. The mean difference (MD) and 95% confidence interval (95% CI) were estimated using the random-effects method. Thirteen trials comprising 1229 participants (mean age 60 years) were identified. The results of our highest versus lowest analysis revealed that MA supplementation was not associated with any increase in body weight (MD: 0.64 kg, 95% CI [-0.11, 1.38], P = 0.093, I
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Haematology-Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences
ID : 62676
Informations de copyright
© 2024 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.
Références
Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017;36:49–64.
Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res 2020;12:5597–5605.
Esper DH, Harb WA. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract 2005;20:369–376.
Mason MC, Garcia JM, Sansgiry S, Walder A, Berger DH, Anaya DA. Preoperative cancer cachexia and short‐term outcomes following surgery. J Surg Res 2016;205:398–406.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.
Argilés JM, Busquets S, Stemmler B, López‐Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14:754–762.
Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381–410.
Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966–973.
Arends J, Strasser F, Gonella S, Solheim T, Madeddu C, Ravasco P, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO open 2021;6:100092.
Prevost V, Grach MC. Nutritional support and quality of life in cancer patients undergoing palliative care. Eur J Cancer Care 2012;21:581–590.
Garcia JM, Shamliyan TA. Off‐label megestrol in patients with anorexia–cachexia syndrome associated with malignancy and its treatments. Am J Med 2018;131:623–9. e1.
Garcia VR, López‐Briz E, Sanchis RC, Perales JLG, Bort‐Martí S. Megestrol acetate for treatment of anorexia–cachexia syndrome. Cochrane Database Syst Rev 2013.
Mazzotta P, Jeney CM. Anorexia–cachexia syndrome: a systematic review of the role of dietary polyunsaturated fatty acids in the management of symptoms, survival, and quality of life. J Pain Symptom Manage 2009;37:1069–1077.
Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin‐6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2003;58:M165–M170.
Zhan P, Wang Q, Qian Q, Yu L‐K. Megestrol acetate in cancer patients with anorexia–cachexia syndrome: a meta‐analysis. Transl Cancer Res 2013;2:74–79.
Ruiz‐García V, López‐Briz E, Carbonell‐Sanchis R, Bort‐Martí S, Gonzálvez‐Perales JL. Megestrol acetate for cachexia–anorexia syndrome. A systematic review. J Cachexia Sarcopenia Muscle 2018;9:444–452.
Lim YL, Teoh SE, Yaow CYL, Lin DJ, Masuda Y, Han MX, et al. A systematic review and meta‐analysis of the clinical use of megestrol acetate for cancer‐related anorexia/cachexia. J Clin Med 2022;11:3756.
Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R. Supportive use of megestrol acetate in patients with head and neck cancer during radio (chemo) therapy. Eur J Cancer 1997;33:75–79.
De Conno F, Martini C, Zecca E, Balzarini A, Venturino P, Groff L, et al. Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. Eur J Cancer 1998;34:1705–1709.
Kanat O, Cubukcu E, Avci N, Budak F, Ercan I, Canhoroz M, et al. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori J 2013;99:229–233.
Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279–1282.
McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, Stevens M, et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2002;52:1180–1185.
Vadell C, Seguí MA, Giménez‐Arnau JM, Morales S, Cirera L, Bestit I, et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 1998;21:347–351.
Westman G, Bergman B, Albertsson M, Kadar L, Gustavsson G, Thaning L, et al. Megestrol acetate in advanced, progressive, hormone‐insensitive cancer. Effects on the quality of life: a placebo‐controlled, randomised, multicentre trial. Eur J Cancer 1999;35:586–595.
Ma Y, Zhao W, Deng W, Wei C, Bie L, Zhang C, et al. Megestrol acetate dispersible tablets with a 5‐HT3 receptor antagonist and dexamethasone vs. 5‐HT3 receptor antagonist plus dexamethasone, can better control chemotherapy‐induced nausea and vomiting: a randomized controlled study. 2022;10:
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. 2021;10:1–11.
Schunemann H. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2. http://www.cc‐ims.net/gradepro. 2008;
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
Higgins JP. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration www.cochrane‐handbook.org 2011;
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta‐analysis. John Wiley & Sons; 2021.
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019.
Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose‐response studies. Biometrics 2005;61:738–748.
Higgins JP. Green S. Cochrane handbook for systematic reviews of interventions version. 2011;5:3.
Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta‐analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119–1129.
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–406.
Ge L, Sadeghirad B, Ball GD, da Costa BR, Hitchcock CL, Svendrovski A, et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta‐analysis of randomised trials. 2020;369:
Bedard G, Zeng L, Zhang L, Lauzon N, Holden L, Tsao M, et al. Minimal clinically important differences in the Edmonton symptom assessment system in patients with advanced cancer. J Pain Sympt Manag 2013;46:192–200.
Hong F, Bosco JL, Bush N, Berry DLJB. Patient self‐appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy. BMC Cancer 2013;13:1–8.
Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE. Wilwerding MB, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia 1999;17:3299–3306.
McMillan D, Simpson J, Preston T, Watson W, Fearon K, Shenkin A, et al. Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clin Nutr 1994;13:85–89.
Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268–1274.
Madeddu C, Dessì M, Panzone F, Serpe R, Antoni G, Cau MC, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clin Nutr 2012;31:176–182.
Beller E, Tattersall M, Lumley T, Levi J, Dalley D, Olver I, et al. Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Ann Oncol 1997;8:277–283.
McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994;265:99–102.
Argilés JM, Anguera A, Stemmler B. A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. Clin Nutr 2013;32:319–324.
Clarick RH, Hanekom WA, Yogev R, Chadwick EG. Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. Pediatrics 1997;99:354–357.